Your browser doesn't support javascript.
loading
Improving the developability profile of pyrrolidine progesterone receptor partial agonists.
Kallander, Lara S; Washburn, David G; Hoang, Tram H; Frazee, James S; Stoy, Patrick; Johnson, Latisha; Lu, Qing; Hammond, Marlys; Barton, Linda S; Patterson, Jaclyn R; Azzarano, Leonard M; Nagilla, Rakesh; Madauss, Kevin P; Williams, Shawn P; Stewart, Eugene L; Duraiswami, Chaya; Grygielko, Eugene T; Xu, Xiaoping; Laping, Nicholas J; Bray, Jeffrey D; Thompson, Scott K.
Afiliação
  • Kallander LS; Department of Chemistry, Metabolic Pathways Centre for Excellence in Drug Discovery, GlaxoSmithKline Pharmaceuticals, 709 Swedeland Road, King of Prussia, PA 19406, USA. lara.s.kallander@gsk.com
Bioorg Med Chem Lett ; 20(1): 371-4, 2010 Jan 01.
Article em En | MEDLINE | ID: mdl-19926282
ABSTRACT
The previously reported pyrrolidine class of progesterone receptor partial agonists demonstrated excellent potency but suffered from serious liabilities including hERG blockade and high volume of distribution in the rat. The basic pyrrolidine amine was intentionally converted to a sulfonamide, carbamate, or amide to address these liabilities. The evaluation of the degree of partial agonism for these non-basic pyrrolidine derivatives and demonstration of their efficacy in an in vivo model of endometriosis is disclosed herein.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pirrolidinas / Receptores de Progesterona Limite: Animals / Female / Humans Idioma: En Ano de publicação: 2010 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pirrolidinas / Receptores de Progesterona Limite: Animals / Female / Humans Idioma: En Ano de publicação: 2010 Tipo de documento: Article